Revisiting Our Eli Lilly Thesis After the GLP-1 Revenue Surge

Our earlier analysis flagged three things to watch: manufacturing capacity as the binding constraint on revenue, competitive threats from Novo Nordisk's semaglutide franchise, and the sustainability of GLP-1 pricing as payers pushed back on reimbursement. We were right on the first point — the FCF collapse in 2024 was entirely driven by the $10 billion-plus capital programme to build out manufacturing. That investment is now generating returns.

On competition, the picture has evolved. Novo remains the dominant player in diabetes-focused GLP-1s, but Lilly has carved out a clear lead in the obesity indication, where Zepbound's weight loss efficacy data continues to outperform. The total addressable market for obesity treatment has expanded dramatically as insurers — initially reluctant — have begun covering the drug class more broadly.

Pricing remains the wild card. We will come back to that.

Here is where our updated thesis gets more nuanced than the original. At $936 per share and a $837.4 billion market cap, Lilly trades at 40.8x trailing earnings and 27.5x forward. The Wall Street consensus target of $1,209 implies 29% upside.

Twelve months ago, we argued the premium was justified because the market was underpricing the revenue ramp. That argument is harder to make today. The revenue has arrived. The question now shifts from "will GLP-1 revenue materialise?" to "what is the sustainable growth rate from a $65 billion base?"

Consensus estimates for 2026 project revenue north of $80 billion, implying 23% growth. That is achievable if manufacturing holds up and new indications — MASH, sleep apnoea, cardiovascular risk reduction — receive regulatory approval on schedule. But 23% growth on a $65 billion base is a different proposition from 45% growth on a $45 billion base. The law of large numbers is beginning to apply.

We have tracked pharma mega-franchises for two decades. The pattern is remarkably consistent: hyper-growth for 3-5 years post-launch, followed by a deceleration to 8-12% as the market saturates and competition intensifies. Lilly's GLP-1 franchise is currently in year three.

Operating margins expanded to 44.9% from 35% two years ago — manufacturing leverage at scale. Profit margins hit 31.7%. EPS of $22.92 represents a 70% increase year-on-year.

The balance sheet has absorbed the manufacturing buildout well. Lilly carries elevated debt from the capex programme, but with $9 billion in FCF and improving margins, the debt-to-EBITDA ratio is compressing rapidly. The 0.63% dividend yield looks thin, but dividend growth has been running at 15% annually — sustainable given the FCF trajectory.

The pricing risk deserves a dedicated mention. Medicare Part D redesign and potential international reference pricing could compress GLP-1 margins by 10-15% over the next three to five years. That is real risk, and it is the primary reason we are not adding to our position at current levels despite the strong fundamentals.